Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.

ABSTRACT:

Purpose

Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and rituximab (IR) in previously untreated older patients with MCL (age ≥ 65 years).

Methods

We enrolled 50 patients with MCL in this single-institution, single-arm, phase II clinical trial (NCT01880567). Patients with Ki-67% ≥ 50% and blastoid morphology were excluded. Ibrutinib was administered with rituximab up to 2 years with continuation of ibrutinib alone. The primary objective was to assess the overall response rate and safety of IR. In evaluable samples, whole-exome sequencing and bulk RNA sequencing from baseline tissue samples were performed.

Results

The median age was 71 years (interquartil

SUBMITTER: Jain P 

PROVIDER: S-EPMC8718245 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature